Co-Diagnostics, Inc. to Present at PAG XXVII on January 14 in San Diego
10 January 2019 - 10:30PM
Business Wire
Company Senior Research Scientist will be a
guest speaker of LGC, Biosearch
Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular
diagnostics company with a unique, patented platform for the
development of molecular diagnostic tests, announced today that a
Company Senior Research Scientist will be presenting research into
the SNP genotyping multiplex capabilities of CoPrimers™ at the 27th
International Plant and Genome conference (PAG XXVII), held in San
Diego, California January 12-16, 2019.
Dr. Jana Kent will speak as a guest of LGC, Biosearch
Technologies (LGC), a global leader in the design, development, and
manufacture of sophisticated, custom oligonucleotide-based tools
and associated reagents for applied markets. In October 2018, the
Company and LGC entered into a license agreement related to the use
of the Company’s patented CoPrimer technology. In the Company
announcement for that agreement, CoPrimers were described as highly
complementary to LGC’s existing oligonucleotide and polymerase
chain reaction (PCR) reagent portfolio, and the agreement was
announced as a major industry validation of the CoPrimer
platform.
From the conference website, PAG is the largest agrigenomics
meeting in the world, providing a forum on recent developments and
future plans for plant and animal genome projects and bringing
together over 3,000 leading genetic scientists and researchers in
this field. Dr. Kent will present on January 14 at 1:45 pm in a
session titled “A Novel Multiplex PCR-Based Solution for SNP
Genotyping.” It will include a discussion of previously unannounced
research into using the Company’s CoPrimer technology for SNP
genotyping, including the multiplexing capabilities that allow for
detecting several SNPs in a single PCR reaction tube. The abstract
for this session may be found here, and LGC will be exhibiting in
Booth 119.
Mr. Dwight Egan, CEO of Co-Diagnostics, said, “We are honored to
present with LGC at the PAG conference, arguably the best global
forum for the CoPrimer platform to gain international recognition
for its applications in the ag-bio industry. We believe that the
groundbreaking work Dr. Kent has conducted and will be presenting
in this conference will bring international recognition to our
company’s innovative technology, and that LGC customers will
greatly benefit from the scalability and cost-savings advantages of
adopting CoPrimers in their businesses.”
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular
diagnostics company that develops, manufactures and markets a new,
state-of-the-art diagnostics technology. The Company’s technology
is utilized for tests that are designed using the detection and/or
analysis of nucleic acid molecules (DNA or RNA). The Company also
uses its proprietary technology to design specific tests to locate
genetic markers for use in industries other than infectious disease
and license the use of those tests to specific customers.
Forward-Looking Statements:
This press release contains forward-looking statements.
Forward-looking statements can be identified by words such as
"believes," "expects," "estimates," "intends," "may," "plans,"
"will" and similar expressions, or the negative of these words.
Such forward-looking statements are based on facts and conditions
as they exist at the time such statements are made and predictions
as to future facts and conditions. Forward-looking
statements in this release include statements regarding the (i) use
of funding proceeds, (ii) expansion of product distribution, (iii)
acceleration of initiatives in liquid biopsy and SNP detection,
(iv) use of the Company’s liquid biopsy tests by laboratories, (v)
capital resources and runway needed to advance the Company’s
products and markets, (vi) increased sales in the near-term, (vii)
flexibility in managing the Company’s balance sheet, (viii)
anticipation of business expansion, and (ix) benefits in research
and worldwide accessibility of the CoPrimer technology and its
cost-saving and scientific advantages. Forward-looking statements
are subject to inherent uncertainties, risks and changes in
circumstances. Actual results may differ materially from
those contemplated or anticipated by such forward-looking
statements. Readers of this press release are cautioned not to
place undue reliance on any forward-looking statements. The Company
does not undertake any obligation to update any forward-looking
statement relating to matters discussed in this press release,
except as may be required by applicable securities laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190110005154/en/
Andrew BensonCo-Diagnostics Investor
Relations801-438-1036investors@codiagnostics.com
Co Diagnostics (NASDAQ:CODX)
Historical Stock Chart
From Apr 2024 to May 2024
Co Diagnostics (NASDAQ:CODX)
Historical Stock Chart
From May 2023 to May 2024